Prostate News Archive
14-Apr-2009
Potential New Target For Treatment Of Hormone Refractory Prostate Cancer (Science Daily)
A new study identifies a protein that modifies the androgen receptor and influences its ability to regulate target genes linked with the progression of prostate cancer. The research may also drive creation of new strategies for the treatment of advanced prostate cancer that no longer responds to traditional anti-hormone therapies. (AFX UK Focus) 2009-04-14 00:04 UPDATE 1-Dendreon to unveil Provenge prostate cancer data (Interactive Investor)
NEW YORK, April 13 (Reuters) - Dendreon Corp on Monday said it would hold a conference call with investors on Tuesday to discuss long-awaited results from a late-stage study of its Provenge treatment for prostate cancer. The biotechnology company declined late Monday to comment on findings from the two-year study, called IMPACT. The study includes more than 500 men with late-stage prostate ... Dendreon to disclose Provenge data for prostate cancer Tuesday (Seattle Times)
Dendreon said it will disclose Tuesday the results of a long-awaited clinical trial of Provenge, its immunotherapy treatment for advanced prostate cancer.
Back to Prostate News Archive
